Litigation Details for Cephalon Inc. v. Watson Laboratories Inc. (D. Del. 2010)

Cephalon Inc. v. Watson Laboratories Inc. (D. Del. 2010)

Docket		Date Filed	2010-01-05
Court	District Court, D. Delaware	Date Terminated	2013-03-30
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand		Referred To
Patents	7,132,570
Link to Docket	External link to docket

Details for Cephalon Inc. v. Watson Laboratories Inc. (D. Del. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-01-05				External link to document

Cephalon Inc. v. Watson Laboratories Inc. Litigation Summary and Patent Analysis, 1:10-cv-00007

Last updated: August 4, 2026

Cephalon Inc. v. Watson Laboratories Inc., No. 1:10-cv-00007, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Watson's abbreviated new drug application for generic modafinil, the active ingredient in Cephalon's Provigil. The dispute centered on Cephalon patents covering modafinil pharmaceutical compositions and related formulation characteristics. The litigation reached the Federal Circuit, which held the asserted claims invalid for obviousness. That ruling materially weakened Cephalon's ability to use the asserted patents to delay generic entry.[1]

What drug and regulatory filing were at issue in Cephalon v. Watson?

The case concerned Provigil, a prescription product containing modafinil. The FDA approved Provigil under NDA No. 020717 for narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift-work sleep disorder.[2]

Watson challenged Cephalon's listed patents through a Paragraph IV certification in connection with its ANDA for generic modafinil tablets. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product. Cephalon responded by filing suit under 35 U.S.C. § 271(e)(2), creating the statutory 30-month stay of FDA approval.

Item	Detail
Brand product	Provigil
Active ingredient	Modafinil
NDA holder at relevant time	Cephalon Inc.
NDA number	020717
Generic applicant	Watson Laboratories Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:10-cv-00007
Legal pathway	ANDA Paragraph IV patent litigation
Principal patents on appeal	U.S. Patent Nos. 6,903,083 and 7,297,346
Federal Circuit decision	707 F.3d 1330 (Fed. Cir. 2013)

What patents protected Provigil in the Watson litigation?

The Federal Circuit appeal focused on U.S. Patent Nos. 6,903,083 and 7,297,346. The patents were directed to modafinil compositions and formulation parameters relevant to the commercial Provigil product.[1]

U.S. Patent No. 6,903,083

The '083 patent covered pharmaceutical compositions containing modafinil. Its claims were directed to formulation subject matter rather than merely the existence of modafinil as an active pharmaceutical ingredient.

The patent was important because formulation claims can remain commercially relevant after basic compound protection expires. A generic applicant may avoid a formulation patent by changing excipients, particle characteristics, manufacturing conditions, or dosage-form architecture. Cephalon asserted that Watson's proposed product would infringe the relevant claims.

U.S. Patent No. 7,297,346

The '346 patent was related to modafinil composition technology and was also asserted against Watson. It represented a later-generation patent position covering aspects of the product formulation and helped extend the patent estate beyond earlier modafinil protection.

The appellate record treated the asserted claims of both patents as obvious in view of the prior art. The ruling therefore affected more than a single claim set. It reduced the practical value of the formulation-based patent strategy used to protect Provigil.

Earlier and other Provigil patents

Cephalon's broader Provigil estate included earlier modafinil patents and additional Orange Book-listed patents. The most commercially significant earlier patent was U.S. Patent No. 5,618,845, associated with modafinil and having an expiration date in 2014, subject to applicable patent-term adjustments or extensions. The '845 patent was part of the wider Provigil patent program but was not the sole basis of the Federal Circuit ruling in the Watson appeal.

The Watson decision should therefore be read as a ruling on the asserted patents in that action, not as a judicial invalidation of every patent ever associated with Provigil.

What was the litigation timeline in 1:10-cv-00007?

Date	Event
January 7, 2010	Cephalon filed the Delaware action against Watson
2010	Watson defended against Cephalon's infringement claims based on its Paragraph IV certification
2011-2012	The district court conducted the merits proceedings concerning the asserted modafinil patents
2012	The district court entered judgment adverse to Cephalon on the asserted patent claims
2013	The Federal Circuit issued its decision in Cephalon v. Watson, 707 F.3d 1330
February 2013	The Federal Circuit affirmed the obviousness determination concerning the asserted claims

The Federal Circuit reviewed the district court's factual findings under the applicable appellate standards and upheld the legal conclusion that the asserted claims were obvious.[1]

What did the Federal Circuit decide in Cephalon v. Watson?

The Federal Circuit affirmed the determination that the asserted claims of the '083 and '346 patents were invalid for obviousness under 35 U.S.C. § 103.[1]

The court's analysis addressed whether a person of ordinary skill in the art would have had a reason to pursue the claimed modafinil formulation and would have had a reasonable expectation of success. The court considered the prior art, formulation practices, and the evidence presented at trial.

The ruling had three principal consequences:

1. Cephalon could not rely on the asserted claims to establish infringement liability against Watson.
2. The asserted formulation patents could not block FDA approval or commercial launch of Watson's ANDA product.
3. The decision weakened the ability of Cephalon to extend Provigil exclusivity through incremental formulation patents.

The decision did not hold that modafinil itself was unpatentable in every respect. It addressed the asserted claims and the specific prior art record developed in the litigation.

How strong was Cephalon's Provigil patent estate after the decision?

The estate was commercially important but legally weakened. The basic product had a mature life-cycle position, while later patents attempted to preserve protection through formulation and composition claims.

Strengths

Cephalon's position had several advantages before the ruling:

• Provigil had substantial FDA and commercial adoption.
• The product had multiple patents and patent families.
• Formulation patents could create a second layer of protection after earlier compound-related rights.
• A Paragraph IV filing triggered litigation and delayed FDA approval under the Hatch-Waxman framework.
• Cephalon had significant resources to litigate against multiple generic applicants.

Weaknesses

The Watson decision exposed structural vulnerabilities:

• The asserted formulation claims were found obvious.
• Modafinil was a known active ingredient with an established clinical and commercial history.
• Later patents had to distinguish the product through formulation details rather than a new chemical entity.
• Generic applicants could challenge the estate without relying solely on an invalidity attack against the original modafinil patent.
• Parallel litigation involving other generic applicants created the risk of inconsistent outcomes and pressure for commercial settlements.

The decision is often cited in pharmaceutical patent analysis as an example of the difficulty of defending formulation patents where the claimed variables reflect routine optimization of known pharmaceutical technology.[1]

What was the Orange Book status of Provigil?

Provigil was listed in the FDA Orange Book with patents covering the product and its approved uses. Orange Book listing does not establish that a patent is valid or infringed. It provides the regulatory framework through which an ANDA applicant makes a Paragraph IV certification and through which the brand company may invoke the 30-month stay.[2]

The key regulatory distinction is:

• A listed patent may delay FDA approval after a timely infringement suit.
• A district court judgment of invalidity can remove the practical blocking effect of the asserted patent.
• FDA approval timing depends on the ANDA record, exclusivity periods, litigation outcomes, and any settlement or court order.

The Watson ruling did not itself establish the expiration date of every Provigil patent listed in the Orange Book. It determined the legal status of the asserted claims in the case.

When did Provigil lose exclusivity and when could generic modafinil launch?

Provigil had already passed the period of new chemical entity exclusivity before the Watson action. The remaining barriers were patent protection, the Hatch-Waxman 30-month stay, and any first-filer or settlement-related restrictions.

The principal commercial exposure arose from the approaching expiration or defeat of the listed patents. Generic modafinil entered the U.S. market in 2012, with multiple generic manufacturers participating in the market after patent litigation and related commercial arrangements were resolved.[3][4]

The precise launch date for any particular Watson product depends on Watson's ANDA status and commercial arrangements. The Federal Circuit decision removed the asserted patent claims as a reliable barrier, but it did not independently order FDA approval or establish a universal launch date for every applicant.

Which companies challenged Cephalon's Provigil patents?

Cephalon faced a broader group of generic challenges involving companies including Watson, Teva, Mylan, Ranbaxy, and Barr Laboratories. The litigation landscape was commercially significant because multiple ANDA applicants could challenge the same or overlapping Provigil patents.

The broader Provigil patent disputes later became the subject of Federal Trade Commission scrutiny. The FTC alleged that Cephalon entered agreements with generic companies that delayed generic entry in exchange for payments or other value. In 2015, the FTC and Cephalon reached a settlement resolving the agency's enforcement action, while private antitrust litigation continued in related proceedings.[3][4]

The existence of settlements in the broader Provigil litigation does not establish that the Watson case itself ended through a settlement. The reported Federal Circuit decision reflects a merits ruling on the asserted patents.

Did Cephalon and Watson enter a settlement agreement?

The public appellate record identifies the Watson matter as a merits patent appeal resulting in an obviousness ruling. The principal legal outcome was the invalidity judgment affirmed by the Federal Circuit, not a publicly reported settlement-based launch compromise.

This differs from Cephalon's broader Provigil litigation strategy, which included settlements with other generic manufacturers. Those agreements were examined in FTC proceedings and private antitrust litigation. A settlement in one Provigil case cannot be treated as evidence of a settlement in 1:10-cv-00007.

What patent litigation affected generic modafinil entry?

Generic entry was affected by four overlapping factors:

1. Cephalon's Orange Book-listed patents.
2. Paragraph IV certifications filed by multiple generic applicants.
3. The statutory 30-month FDA approval stay.
4. Commercial settlements and the subsequent invalidity rulings.

The Watson decision was particularly important because it eliminated two formulation-based patents as effective litigation barriers. The broader market remained subject to other patents, regulatory requirements, and applicant-specific issues, but Cephalon's formulation protection became materially less durable after the Federal Circuit ruling.

What generic launch risks remained after the Watson decision?

After the decision, a generic modafinil applicant still faced several risks:

• Other unexpired patents might remain listed or enforceable.
• The applicant could face separate litigation from Cephalon or another patent owner.
• FDA approval could remain pending for regulatory reasons unrelated to patent validity.
• First-filer exclusivity could affect approval timing for other ANDA applicants.
• A later patent or method-of-use claim could create a narrower litigation risk.
• Commercial launch could trigger damages exposure if an appellate stay or other legal restriction applied.

For Cephalon, the principal risk was price erosion. Modafinil tablets are chemically and therapeutically mature, and generic substitution can produce rapid market-share loss once several approved products enter.

What was the commercial impact of the Watson case?

Provigil was one of Cephalon's largest products. Cephalon reported Provigil net sales of approximately $1.1 billion in 2011, before the full impact of generic competition.[5] The product represented a substantial portion of Cephalon's revenue and acquisition value when Teva agreed to acquire Cephalon in 2011.[6]

Generic entry exposed Cephalon to:

• Lower net pricing.
• Rapid pharmacy substitution.
• Reduced branded market share.
• Lower royalty and licensing value for Provigil-related rights.
• Reduced leverage in settlements with remaining generic applicants.
• Pressure to shift demand toward newer products such as Nuvigil.

The case also illustrates a common life-cycle management risk: formulation patents can generate meaningful exclusivity only if their claim scope withstands obviousness scrutiny and covers the commercial product without requiring commercially unattractive design choices.

How does Provigil patent protection compare with Nuvigil?

Provigil contains modafinil, while Nuvigil contains armodafinil, the R-enantiomer of modafinil. Cephalon used Nuvigil as a follow-on product before generic Provigil entry.

Factor	Provigil	Nuvigil
Active ingredient	Modafinil	Armodafinil
Product type	Racemic modafinil product	Single-enantiomer product
FDA approval	1998	2007
Strategic role	Original franchise product	Follow-on life-cycle product
Main patent risk	Mature composition and formulation estate	Later compound, formulation, and method-of-use estate
Generic risk	High after 2012 entry	Later but still exposed to Paragraph IV challenges

Nuvigil's later approval gave Cephalon additional commercial runway, but it did not preserve Provigil's monopoly. The products were related but not interchangeable from a patent standpoint.

Key Takeaways

• Cephalon sued Watson in Delaware in 2010 over an ANDA for generic modafinil.
• The principal appellate patents were U.S. Patent Nos. 6,903,083 and 7,297,346.
• The Federal Circuit affirmed that the asserted claims were invalid for obviousness in 707 F.3d 1330.
• The ruling weakened Cephalon's formulation-based strategy for extending Provigil exclusivity.
• The case was part of a wider Provigil patent and settlement landscape involving Teva, Mylan, Ranbaxy, Barr, and other generic companies.
• Generic modafinil entered the U.S. market in 2012, creating substantial revenue and pricing exposure for Cephalon.
• The decision did not invalidate every Provigil-related patent or determine the status of all Orange Book listings.
• Provigil's patent risk should be analyzed separately from Nuvigil's later and distinct patent estate.

FAQs About Cephalon v. Watson and Provigil Patent Litigation

What was the main patent issue in Cephalon v. Watson?

The main issue was whether claims covering modafinil pharmaceutical compositions and related formulation characteristics were valid and infringed by Watson's proposed generic product. The Federal Circuit upheld the obviousness determination against the asserted claims.

Did Watson win approval for generic modafinil?

The Federal Circuit ruling removed the asserted patents as a blocking basis, but the decision itself did not grant FDA approval. Approval depended on Watson's ANDA and the applicable FDA and Hatch-Waxman requirements.

Was Provigil protected by a compound patent or only formulation patents?

Provigil was associated with both earlier modafinil-related patents and later composition and formulation patents. The Watson appeal focused on later formulation-related patents, not every patent in Cephalon's portfolio.

Did the Watson case invalidate Cephalon's entire Provigil patent estate?

No. The judgment concerned the asserted claims in the specific action. Other patents, patent families, method-of-use claims, and regulatory exclusivities required separate analysis.

Why was the case important for pharmaceutical patent strategy?

The case demonstrates that formulation patents covering a known active ingredient can fail under obviousness where the claimed formulation reflects predictable optimization and the prior art provides a reason to pursue the claimed parameters.

References

1. U.S. Court of Appeals for the Federal Circuit. (2013). Cephalon, Inc. v. Watson Pharmaceuticals, Inc., 707 F.3d 1330.
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
3. Federal Trade Commission. (2015). FTC v. Cephalon, Inc., settlement materials and related enforcement proceedings.
4. U.S. District Court for the Eastern District of Pennsylvania. (2016). In re Modafinil Antitrust Litigation, related private antitrust proceedings.
5. Cephalon, Inc. (2011). Annual report on Form 10-K for the year ended December 31, 2011.
6. Teva Pharmaceutical Industries Ltd. (2011). Teva completes acquisition of Cephalon.